IONS
NASDAQIonis Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$74.79-1.55 (-2.03%)
01:30 PM07:45 PM
News · 26 weeks125+23%
2025-11-022026-04-26
Mix6590d
- Insider36(55%)
- Other13(20%)
- SEC Filings11(17%)
- Earnings2(3%)
- Analyst2(3%)
- Leadership1(2%)
Latest news
25 items- INSIDEREVP, Chief Business Officer Baroldi Joseph sold $116,727 worth of shares (1,626 units at $71.79) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 44,909 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- SECSEC Form 10-Q filed by Ionis Pharmaceuticals Inc.10-Q - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- PRIonis reports first quarter 2026 financial results and highlights progress on key programs- TRYNGOLZA® (olezarsen) showed increasing demand in FCS driven by strong launch execution – - Olezarsen sNDA accepted by the FDA for Priority Review; sHTG launch preparations on track – – Increasing annual TRYNGOLZA peak net sales guidance to >$3B for sHTG – - Zilganersen NDA for Alexander disease accepted for Priority Review, paving way for Ionis' first independent launch from leading neurology pipeline – - Strong first-quarter performance and outlook for the year supports improved 2026 financial guidance - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results and provided key updates for the first quarter ended March 31, 2026. "Ionis' stro
- PRIonis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B– Regulatory submission supported by Phase 3 B-Well trials demonstrating statistically significant and clinically meaningful functional cure rates in chronic hepatitis B - – Breakthrough Therapy designation added to Fast Track Designation, recognizing potential for substantial improvement over existing treatments – – Chronic hepatitis B is a leading cause of liver cancer globally – – PDUFA Date of October 26, 2026 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) partner GSK today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of adu
- SECSEC Form DEFA14A filed by Ionis Pharmaceuticals Inc.DEFA14A - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- SECSEC Form DEF 14A filed by Ionis Pharmaceuticals Inc.DEF 14A - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- ANALYSTCanaccord Genuity initiated coverage on Ionis Pharma with a new price targetCanaccord Genuity initiated coverage of Ionis Pharma with a rating of Buy and set a new price target of $110.00
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- PRIonis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting– New data highlight potential treatment benefit across multiple AxD symptom domains, reinforcing zilganersen's positive impact on people living with this rare, often fatal neurological disease – – PDUFA date set for September 22, 2026 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. These findings, which will be presented today at the 2026 American Academy of Neurology (AAN) annual meeting, build on previously reported positive topline data and pr
- INSIDERSEC Form 4 filed by Jenne Kyle4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Parshall B Lynne4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Birchler Brian4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Baroldi Joseph4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- PRIonis to hold first quarter 2026 financial results webcastWebcast scheduled for Wednesday, April 29 at 8:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that it will host a live webcast on Wednesday, April 29 at 8:30 a.m. Eastern Time to discuss its first quarter 2026 financial results and highlight progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabol
- ANALYSTRaymond James resumed coverage on Ionis Pharma with a new price targetRaymond James resumed coverage of Ionis Pharma with a rating of Outperform and set a new price target of $104.00
- INSIDERSEC Form 4 filed by Klein Joseph Iii4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Devers Shannon L.4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- PRFDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular AtrophyThe approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patientsHigh Dose SPINRAZA will be available in the United States in the coming weeks and is also approved in the European Union, Switzerland and Japan CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of spinal muscular atrophy (SMA). Backed by more than 10 years of cli
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ionis Pharmaceuticals Inc.SCHEDULE 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
- SECAmendment: SEC Form 144/A filed by Ionis Pharmaceuticals Inc.144/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
- INSIDERSEC Form 4 filed by Schneider Eugene4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- PRIonis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review– PDUFA date set for September 22, 2026 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), a rare, progressive and often fatal neurological condition. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2026. "Alexander disease is a devastating condition, commonly resulting in progressive motor and cognitive dysfunction, loss of independence and is often fatal. There are no approved disease-modifying treatments, underscoring the significant
- INSIDERSEC Form 4 filed by Ionis Pharmaceuticals Inc.4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERChief Executive Officer Monia Brett P sold $12,114,155 worth of shares (160,773 units at $75.35) and exercised 148,454 shares at a strike of $60.89, decreasing direct ownership by 5% to 242,662 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
IONS FAQ
6 questionsWhat does Ionis Pharmaceuticals Inc. do?
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases...Where does IONS stock trade?
Ionis Pharmaceuticals Inc. (IONS) is listed on NASDAQ.What sector and industry is IONS in?
Ionis Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IONS?
Ionis Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-04-21.What companies are similar to IONS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare IONS side-by-side with any of them on Quantisnow.How can I track IONS on Quantisnow?
Quantisnow aggregates Ionis Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IONS to receive live email and push alerts on every new disclosure.